Novartis Says Early-to-Mid Stage Study for Muscular Dystrophy Drug Meets Main Goal

MT Newswires Live06-11

Novartis (NVS) said Thursday a phase I/II study of its experimental therapy, del-brax, met both primary and key secondary endpoints in patients with facioscapulohumeral muscular dystrophy.

The drugmaker said the drug reduced levels of KHDC1L, a biomarker linked to the disease's underlying cause, and lowered creatine kinase levels, a marker of muscle damage, compared with placebo.

Del-brax, designed to target DUX4, a protein that drives the condition was acquired through Novartis' purchase of Avidity Biosciences earlier this year, the company said.

Based on study, Novartis said it is enrolling about 200 patients in the phase 3 study to evaluate the drug's safety and effectiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment